Key Highlights

  • Third-quarter Revenue rose 8.4% to USD 3,179 thousand.
  • BioNx biomaterial revenue was USD 881 thousand.
  • Gross Margin was 35.4%, against 42.4%.
  • Third-quarter net loss was USD 1,093 thousand.

The new BioNx Business explains both the revenue gain and the larger loss at NexGel (NASDAQ:NXGL). Third-quarter revenues were USD 3,179 thousand versus USD 2,934 thousand, up USD 245 thousand, or 8.4%. New biomaterial revenue of USD 881 thousand was partly offset by drops of USD 442 thousand in consumer branded products and USD 171 thousand in contract manufacturing.

Gross profit was USD 1,125 thousand versus USD 1,243 thousand, and gross margin was 35.4% versus 42.4%, reflecting initial biomaterial sales at lower margin and higher inventory write-offs, freight and Royalty costs. Cost of revenues rose 21.5% to USD 2,054 thousand. The net loss was USD 1,093 thousand versus USD 647 thousand, and the net loss attributable to stockholders was USD 1,112 thousand, or USD 2.28 per share.

What BioNx Added

Selling, general and administrative expenses rose USD 1,703 thousand, or 86.8%, to USD 3,664 thousand, including USD 702 thousand to establish and run the BioNx Surgical division and USD 1,134 thousand of amortization of the Celularity license intangible.

Since April 2026, after acquiring an exclusive license to, and certain Assets of, Celularity's portfolio of commercial-stage regenerative biomaterials, the company sells products for tendon repair, soft tissue reconstruction and bone regeneration under the BioNx brand. It now reports five lines of business: contract manufacturing, custom and white label, consumer branded products, medical devices and other, and BioNx.

Nine Months

Revenues were USD 9,515 thousand versus USD 8,625 thousand, up 10.3%, driven by USD 1,695 thousand of biomaterial sales and partly offset by a USD 730 thousand fall in consumer branded products. Gross Profit was USD 3,294 thousand versus USD 3,690 thousand, and gross margin was 34.6% versus 42.8%.

Selling, general and administrative expenses rose 59.4% to USD 9,277 thousand, including USD 1,359 thousand for BioNx Surgical and USD 1,890 thousand of license amortization. The net loss was USD 5,572 thousand versus USD 1,965 thousand, or USD 12.61 per share attributable to stockholders versus USD 5.23, and the loss from operations was USD 6,003 thousand.

Cash, Working Capital and Going Concern

The company held USD 658 thousand of cash and restricted cash at September 30, 2026, of which USD 278 thousand was unrestricted, versus USD 1,058 thousand at year end. Investing activities used USD 6,620 thousand, mainly a USD 6,503 thousand cash payment for the Celularity license and related assets, while financing provided USD 10,052 thousand, including USD 11,140 thousand of net proceeds from convertible notes.

Current assets were USD 4,936 thousand against current liabilities of USD 10,626 thousand, leaving negative working capital of USD 5,690 thousand versus positive USD 1,382 thousand at year end. The company cites a USD 4,584 thousand rise in non-cash derivative liability. Its financial statements make no adjustments for a failure to continue as a going concern, and it expects to keep incurring losses in the near term. A 50% joint venture with CG Laboratories, CG Converting and Packaging in Granbury, Texas, supports finished goods delivery.

Where the Quarter Leaves NexGel

The BioNx launch is lifting revenue but at lower margin and with heavy start-up and amortization costs, while cash is thin and working capital is negative. Biomaterial sales growth, gross margin and funding are the points to follow.